Charlotte Harrison
@charlotteh560.bsky.social
Freelance science writer and editor
Researchers are increasingly using organ chips and organoids alongside or instead of animals to model drug safety, biological mechanisms and rare diseases. My latest for Lab Animal @natureportfolio.nature.com rdcu.be/eH7Pj
With insight from @nc3rs.bsky.social @emulatebio.bsky.social and others
With insight from @nc3rs.bsky.social @emulatebio.bsky.social and others
New approach methodologies gain momentum, providing human-relevant alternatives to animal models
Lab Animal - Researchers are increasingly using organ-on-chips and organoids alongside or instead of animals to model drug safety, biological mechanisms and rare diseases.
rdcu.be
September 26, 2025 at 10:04 AM
Researchers are increasingly using organ chips and organoids alongside or instead of animals to model drug safety, biological mechanisms and rare diseases. My latest for Lab Animal @natureportfolio.nature.com rdcu.be/eH7Pj
With insight from @nc3rs.bsky.social @emulatebio.bsky.social and others
With insight from @nc3rs.bsky.social @emulatebio.bsky.social and others
Can amylin-based drugs upstage GLP-1 agonists? They could avoid muscle loss and gastrointestinal side effects of current obesity therapies. My latest for @natbiotech.nature.com rdcu.be/ezwbM
Can amylin-based drugs upstage GLP-1 agonists?
Nature Biotechnology - Analogs of the pancreatic peptide hormone amylin are making strides in obesity as developers zoom in on oral drugs that can emulate or even improve on injectable GLP-1...
rdcu.be
August 6, 2025 at 1:09 PM
Can amylin-based drugs upstage GLP-1 agonists? They could avoid muscle loss and gastrointestinal side effects of current obesity therapies. My latest for @natbiotech.nature.com rdcu.be/ezwbM
Reposted by Charlotte Harrison
Biopharma dives into tumor-seeking radioactive drugs www.nature.com/articles/s41...
Biopharma dives into tumor-seeking radioactive drugs - Nature Biotechnology
Big pharma and investors are piling into the precision radiation space as the next generation of increasingly potent targeted α-particle therapies promises to destroy cancerous cells with minimum dama...
www.nature.com
May 19, 2025 at 1:57 PM
Biopharma dives into tumor-seeking radioactive drugs www.nature.com/articles/s41...
Hello Bluesky! Let’s try a first post…here’s my latest story for @naturebiotech.bsky.social on @vertexpharma.bsky.social non-opioid pain killer and next-gen NaV1.8 inhibitors in the pipeline rdcu.be/ealj0
Vertex’s opioid-free drug for acute pain wins FDA approval
Nature Biotechnology - Society, patients and clinicians welcome a much-needed non-opioid pain medication. Vertex’s first-in-class analgesic Journavx could soon be followed by a new generation...
rdcu.be
February 18, 2025 at 1:03 PM
Hello Bluesky! Let’s try a first post…here’s my latest story for @naturebiotech.bsky.social on @vertexpharma.bsky.social non-opioid pain killer and next-gen NaV1.8 inhibitors in the pipeline rdcu.be/ealj0